The Ross Procedure
The Ross Procedure is an operation that uses the patient’s own healthy and living pulmonary valve (pulmonary autograft), which is a mirror image of a normal aortic valve, to replace the damaged aortic valve. A donated human pulmonary valve (pulmonary homograft) is used to replace the pulmonary valve. This is a complex surgical procedure and positive outcomes are dependent on experienced Ross surgeons performing this procedure in high volumes every year.
On-X Aortic Valve
On-X Aortic Valve is the only mechanical valve made of pure pyrolytic carbon designed to last a lifetime and approved to be used safely with less blood thinner.*,1 This results in a significantly lowered risk for bleeding by >60% without a clinical difference in thromboembolic events.2
Tissue (Bioprosthetic) Valve
Tissue (Bioprosthetic) Valves are made with animal tissue, typically pig or cow. Only tissue valves develop structural valve deterioration (SVD) and there are no known medical therapies to prevent or treat SVD.1,2 SVD reintroduces symptoms of valve stenosis and regurgitation, causing patients to feel tired and short of breath as their new aortic valve begins to leak or become stiff and too small again.2-4 Implanted tissue valves that develop SVD may require reintervention, and the younger a patient is when they get a tissue valve, the faster the onset of SVD.1,2
Transcatheter Aortic Valve Replacement (TAVR)
Transcatheter Aortic Valve Replacement (TAVR) is the replacement of the aortic valve through the femoral artery in the groin (transfemoral) or through a small incision in the chest (transapical), historically performed in elderly patients to avoid risk of surgery. The most recent TAVR study with only 1-year of data includes low-risk patients at an average age of 73 years-old.1 TAVR is considered a potential option for some patients with a failed implanted tissue valve, placing a transcatheter tissue valve inside the previous failed tissue valve (Valve-in-Valve). However, no long-term data exists for this option.
MLENG1399.000 (2020-01)
References:
On-X Aortic Heart Valves: *After 3 months standard therapy. See On-X Prosthetic Heart Valve Instructions for Use, https://www.onxlti.com/ifu/hv/, Accessed 12-04-2019. 1. Nishimura RA, et al. J Am Coll Cardiol 2017;70:252-89. 2. Puskas JD, et al. J Am Coll Cardiol 2018;71:2717-26. Tissue (Bioprosthetic) Valve: 1. Nishimura RA, et al. J Am Coll Cardiol 2017;70(2):252-89. 2. Rodriguez-Gabella T, et al. J Am Coll Cardiol 2017;70(8):1013-28. 3. Mayo Clinic, Aortic Valve Stenosis, https://www.mayoclinic.org/diseases-conditions/aortic-stenosis/symptoms-causes/syc-20353139, Accessed 11-25-2019. 4. Mayo Clinic, Aortic Valve Regurgitation, https://www.mayoclinic.org/diseases-conditions/aortic-valve-regurgitation/symptoms-causes/syc-20353129, Accessed 11-25-2019. Transcatheter Aortic Valve Replacement (TAVR): 1. Mack MJ, et al. N Engl J Med 2019;380:1695-1705.